Avandia: The sequel

 - diabetes, pharmaceutical, needle
Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The New York Times set the stage for the upcoming FDA meeting that revisits GlaxoSmithKline’s diabetes drug, rosiglitazone (Avandia). The FDA said it is trying to “resolve uncertainty” about the drug, which has been limited based on concerns about heightened cardiovascular risk.